Clinical Trials Logo

Clinical Trial Summary

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03859427
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Status Not yet recruiting
Phase Phase 3
Start date April 23, 2019
Completion date December 23, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02099539 - QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00545519 - A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Completed NCT01866293 - Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Phase 1/Phase 2
Completed NCT01058434 - Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation Phase 2
Terminated NCT02075021 - Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00478777 - A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Phase 3
Not yet recruiting NCT03837509 - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT02834364 - BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Phase 2
Active, not recruiting NCT03158688 - Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Phase 3
Recruiting NCT02675452 - AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03512353 - A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers Phase 2
Completed NCT00708292 - A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. Phase 1/Phase 2
Recruiting NCT03751293 - A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Phase 1
Recruiting NCT02939183 - Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT03815383 - A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma Phase 1
Completed NCT00642954 - Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) Phase 1
Completed NCT00773838 - Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ) Phase 2
Terminated NCT01670994 - QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT03464916 - Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Phase 1
Completed NCT02046915 - Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide Phase 2